Version history

{
  "pmid": "36628952",
  "doi": "10.2217/pgs-2022-0137",
  "abstract": "1. Pharmacogenomics. 2023 Jan;24(1):27-57. doi: 10.2217/pgs-2022-0137. Epub 2023 \nJan 11.\n\nPharmacogenetics of anxiety and depression in Alzheimer's disease.\n\nCacabelos R(1), Carril JC(2), Corzo L(3), Pego R(4), Cacabelos N(5), Alcaraz \nM(6), Muñiz A(6), Martínez-Iglesias O(7), Naidoo V(8).\n\nAuthor information:\n(1)Department of Genomic Medicine, International Center of Neuroscience & \nGenomic Medicine, EuroEspes Biomedical Research Center, Bergondo, Corunna, \n15165, Spain.\n(2)Department of Genomics & Pharmacogenomics, International Center of \nNeuroscience & Genomic Medicine, EuroEspes Biomedical Research Center, Bergondo, \nCorunna, 15165, Spain.\n(3)Department of Medical Biochemistry, International Center of Neuroscience & \nGenomic Medicine, EuroEspes Biomedical Research Center, Bergondo, Corunna, \n15165, Spain.\n(4)Department of Neuropsychology, International Center of Neuroscience & Genomic \nMedicine, EuroEspes Biomedical Research Center, Bergondo, Corunna, 15165, Spain.\n(5)Department of Medical Documentation, International Center of Neuroscience & \nGenomic Medicine, EuroEspes Biomedical Research Center, Bergondo, Corunna, \n15165, Spain.\n(6)Department of Nursing, International Center of Neuroscience & Genomic \nMedicine, EuroEspes Biomedical Research Center, Bergondo, Corunna, 15165, Spain.\n(7)Department of Medical Epigenetics, International Center of Neuroscience & \nGenomic Medicine, EuroEspes Biomedical Research Center, Bergondo, Corunna, \n15165, Spain.\n(8)Department of Basic Neuroscience, International Center of Neuroscience & \nGenomic Medicine, EuroEspes Biomedical Research Center, Bergondo, Corunna, \n15165, Spain.\n\nAnxiety and depression coexist with cognitive impairment in Alzheimer's disease \nalong with other concomitant disorders (>60%), which require multipurpose \ntreatments. Polypharmaceutical regimens cause drug-drug interactions and adverse \ndrug reactions, potentially avoidable in number and severity with the \nimplementation of pharmacogenetic procedures. The accumulation of defective \nvariants (>30 genes per patient in more than 50% of cases) in pharmagenes \n(pathogenic, mechanistic, metabolic, transporter, pleiotropic) influences the \ntherapeutic response to antidementia, antidepressant and anxiolytic drugs in \npolyvalent regimens. APOE, CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, \nCYP3A5, CYP4F2, COMT, MAOB, CHAT, GSTP1, NAT2, SLC30A8, SLCO1B1, ADRA2A, ADRB2, \nBCHE, GABRA1, HMGCR, HTR2C, IFNL3, NBEA, UGT1A1, ABCB1, ABCC2, ABCG2, SLC6A2, \nSLC6A3, SLC6A4, MTHFR and OPRM1 variants affect anxiety and depression in \nAlzheimer's disease.\n\nDOI: 10.2217/pgs-2022-0137\nPMID: 36628952 [Indexed for MEDLINE]",
  "journal": "Pharmacogenomics",
  "year": 2023,
  "authors": "Cacabelos R, Carril JC, Corzo L, Pego R, Cacabelos N, Alcaraz M, Muñiz A, Martínez-Iglesias O, Naidoo V",
  "url": "https://pubmed.ncbi.nlm.nih.gov/36628952",
  "external_ids": {
    "doi": "10.2217/pgs-2022-0137",
    "pmid": "36628952"
  },
  "citation_count": 1,
  "domain": "neurodegeneration"
}